The clinical use of these compounds as anticancer agents is limited due to lack of tumour selectivity [41], however deactivation of the pharmacophore offers an opportunity to selectively target the oxidative capacity of CYP enzymes overexpressed in tumour tissue to restore the cell-killing ability of these compounds [42,43]. Here, PPIG is linked to neoplasm.